Skip to main content
Livermore
Livermore
ZHEN

Acadia Pharmaceuticals Inc

ACAD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001070494

In the last 90 days, Acadia Pharmaceuticals Inc insiders filed 0 open-market purchases and 2 sales; 353 institutions reported holding it in 13F filings for Q2 2026, worth $4.27B in total; no superinvestor holds it.

Holders of 5% or more of ACAD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Acadia Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ACAD
HolderLatest formStakeChangeFirst filedLatest filingFiling
Baker Bros. Advisors LP13D/A25.40%43.3M shares–Feb 26, 20261 filingFeb 26, 2026SEC
BlackRock, Inc.13G/A11.90%19.9M shares–Feb 7, 20251 filingFeb 7, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Acadia Pharmaceuticals Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ACAD
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 26, 20263:06 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Feb 26, 20266:59 PM ETBaker Bros. Advisors LPand 4 others13D/A25.40%43.3M shares–Feb 24, 2026SEC
Nov 14, 20258:16 AM ETRTW Investments, LPand 1 other13G/A4.20%7.14M shares−1.00 ppfrom 5.20%Below 5%Sep 30, 2025SEC
Feb 14, 20259:00 AM ETRTW Investments, LPand 1 other13G/A5.20%8.71M shares–Dec 31, 2024SEC
Feb 7, 20256:04 AM ETBlackRock, Inc.13G/A11.90%19.9M shares–Jan 31, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Acadia Pharmaceuticals Inc shares.

No Form 144 notices for Acadia Pharmaceuticals Inc are on file.